. . . "Lofexidina"@en . . "31036-80-3"@en . "U.S. Patent 3,966,757."@en . . . . "2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline"@en . . . . . " "@en . . . . . "investigational"@en . "Lofexidinum"@en . . . . "Humans and other mammals"@en . . "approved"@en . . . . . . . "11 hours"@en . "Investigated for use/treatment in addictions and substance abuse."@en . "80 to 90%"@en . "Lofexidine is an alpha2-adrenergic receptor agonist."@en . . "Lofexidine is an alpha2-adrenergic receptor agonist. It can be used as a short acting anti-hypertensive, but is mostly used to help relieve symptoms of heroin or opiate withdrawal in opiate dependency. It is approved in the United Kingdom, but is still undergoing clinical trials in the United States."@en . " "@en . "# Walsh SL, Strain EC, Bigelow GE: Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans. Addiction. 2003 Apr;98(4):427-39. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12653813 # Manufacturer Website \"Link\":http://www.lofexidine.co.uk/main.html"@en . . . . . . . "Lofexidine was tolerated at high dosage in singe dose toxicity studies in animals, the LD₅₀ being >77 mg/kg. With repeat dosing in mice, rats and dogs symptoms related to the pharmacology of the drug (ataxia, sedation, tremor, unkempt appearance and exhaustion) appeared. Overdosage may cause hypotension, bradycardia and sedation. "@en . . "Lofexidine"@en . . . "Lofexidine is extensively absorbed and achieves peak plasma concentration at 3 hours after administration of a single dose. Bioavailability is over 90% following oral administration."@en . . . .